29 Nov, 2022 12:59 PM
MELBOURNE, AUSTRALIA 29 NOVEMBER 2022: Arovella Therapeutics Limited (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform, is leas...read more
07 Nov, 2022 10:14 AM
MELBOURNE, AUSTRALIA 7 November 2022: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform to treat cancer, is plea...read more
29 Jul, 2022 08:46 AM
MELBOURNE, AUSTRALIA 29 July 2022: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform for cancer treatment and it...read more
28 Jun, 2022 09:03 AM
MELBOURNE, AUSTRALIA 28 June 2022: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform and its oral spray delivery...read more
22 Jun, 2022 10:02 AM
Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform and its oral spray delivery technology to treat cancer and con...read more
28 Apr, 2022 11:38 AM
MELBOURNE, AUSTRALIA 28 April 2022: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform and its oral spray deliver...read more
20 Apr, 2022 11:10 AM
Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform to treat blood cancers, is pleased to announce that it has agr...read more
05 Apr, 2022 02:14 PM
Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform to treat blood cancers and a leader in oro-mucosal drug delive...read more